Randomized, double-blind, phase I/II study of intravenous allogeneic mesenchymal stromal cells in acute myocardial infarction

Cytotherapy

Volumn 17, Issue 3, 2015, Pages 250-261

  Chullikana, Anoop ^a,d   Majumdar, Anish Sen ^a,d   Gottipamula, Sanjay ^a,d   Krishnamurthy, Sagar ^a,d   Kumar, A Sreenivas ^b   Prakash, V S ^c   Gupta, Pawan Kumar ^c  

^a Stempeutics Research Pvt Limited   (India)

^b CARE HOSPITAL   (India)

^c MS Ramaiah Medical Hospital   (India)

^d Stempeutics Research Manipal   (India)

Author keywords

Acute myocardial infarction; Bone marrow; Cell therapy; Mesenchymal stromal cells

Indexed keywords

CARDIOVASCULAR AGENT; PLACEBO; STEMPEUCEL; STROMAL CELL DERIVED FACTOR 1; UNCLASSIFIED DRUG;

ACUTE HEART INFARCTION; ADULT; ALLOGENEIC MESENCHYMAL STROMAL CELL; ARTICLE; CLINICAL ARTICLE; CONNECTIVE TISSUE DISEASE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ECHOCARDIOGRAPHY; FATALITY; FEMALE; GASTROINTESTINAL DISEASE; HEART DISEASE; HEART EJECTION FRACTION; HEART INFARCTION; HEART INFARCTION SIZE; HEMATOLOGIC DISEASE; HUMAN; INFECTION; INFESTATION; LYMPHATIC SYSTEM DISEASE; MALE; MEDIASTINUM DISEASE; MESENCHYMAL STROMA CELL; METABOLIC DISORDER; MULTICENTER STUDY; MUSCULOSKELETAL DISEASE; NEUROLOGIC DISEASE; NUCLEAR MAGNETIC RESONANCE IMAGING; NUTRITIONAL DISORDER; PERCUTANEOUS CORONARY INTERVENTION; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT DISEASE; SCORING SYSTEM; SINGLE DRUG DOSE; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; THORAX DISEASE; TREATMENT OUTCOME; ADVERSE EFFECTS; AGED; BIOLOGICAL THERAPY; BONE MARROW CELL; CLINICAL TRIAL; CYTOLOGY; INTRAVENOUS DRUG ADMINISTRATION; MESENCHYMAL STEM CELL TRANSPLANTATION; MIDDLE AGED; MYOCARDIAL INFARCTION; PROCEDURES; YOUNG ADULT;

ADMINISTRATION, INTRAVENOUS; ADULT; AGED; BONE MARROW CELLS; CELL- AND TISSUE-BASED THERAPY; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMAL CELLS; MIDDLE AGED; MYOCARDIAL INFARCTION; PLACEBOS; YOUNG ADULT;

EID: 84924966207     PISSN: 14653249     EISSN: 14772566     Source Type: Journal    
DOI: 10.1016/j.jcyt.2014.10.009     Document Type: Article

References (55)

1. Murray C., Lopez A. The Global Burden of Disease: A Comprehensive Assessment of Mortality and Disability from Disease, Injuries and Risk Factors in 1990 and Projected to 2020 1996, Harvard University Press, Boston, MA.
2. Leistner D.M., Fischer-Rasokat U., Honold J., Seeger F.H., Schächinger V., Lehmann R., et al. Transplantation of progenitor cells and regeneration enhancement in acute myocardial infarction (TOPCARE-AMI): final 5-year results suggest long-term safety and efficacy. Clin Res Cardiol 2011 Oct, 100:925-934.
3. Meyer G.P., Wollert K.C., Lotz J., Steffens J., Lippolt P., Fichtner S., et al. Intracoronary bone marrow cell transfer after myocardial infarction: eighteen months' follow-up data from the randomized, controlled BOOST (BOne marrOw transfer to enhance ST-elevation infarct regeneration) trial. Circulation 2006, 113:1287-1294.
4. Kang H.-J., Lee H.-Y., Na S.-H., Chang S.-A., Park K.-W., Kim H.-K., et al. Differential effect of intracoronary infusion of mobilized peripheral blood stem cells by granulocyte colony-stimulating factor on left ventricular function and remodeling in patients with acute myocardial infarction versus old myocardial infarction: the MAGIC Cell-3-DES randomized, controlled trial. Circulation 2006, 114(1 Suppl):I145-I151.
5. Mansour S, Roy D-C, Bouchard V, Stevens LM, Gobeil F, Rivard A, etal. One-Year Safety Analysis of the COMPARE-AMI Trial: Comparison of Intracoronary Injection of CD133+ Bone Marrow Stem Cells to Placebo in Patients after Acute Myocardial Infarction and Left Ventricular Dysfunction. Bone Marrow Res [Internet]. 2011 [cited 2014 Jun 18];2011. Available from: . http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3200002/.
6. Hare J.M., Traverse J.H., Henry T.D., Dib N., Strumpf R.K., Schulman S.P., et al. Arandomized, double-blind, placebo-controlled, dose-escalation study of intravenous adult human mesenchymal stem cells (prochymal) after acute myocardial infarction. JAm Coll Cardiol 2009, 54:2277-2286.
7. Shim W., Mehta A., Wong P., Chua T., Koh T.H. Critical path in cardiac stem cell therapy: an update on cell delivery. Cytotherapy 2013, 15:399-415.
8. Jeevanantham V., Butler M., Saad A., Abdel-Latif A., Zuba-Surma E.K., Dawn B. Adult bone marrow cell therapy improves survival and induces long-term improvement in cardiac parameters: a systematic review and meta-analysis. Circulation 2012, 126:551-568.
9. Leri A., Anversa P. Stem cells: bone-marrow-derived cells and heart failure-the debate goes on. Nat Rev Cardiol 2013, 10:372-373.
10. Rehman J. Bone marrow tinctures for cardiovascular disease: lost in translation. Circulation 2013, 127:1935-1937.
11. Ryan J.M., Barry F.P., Murphy J.M., Mahon B.P. Mesenchymal stem cells avoid allogeneic rejection. JInflamm (Lond) 2005, 2:8.
12. Jacobs S.A., Pinxteren J., Roobrouck V.D., Luyckx A., van't Hof W., Deans R., et al. Human multipotent adult progenitor cells are nonimmunogenic and exert potent immunomodulatory effects on alloreactive T-cell responses. Cell Transplant 2013, 22:1915-1928.
13. McTaggart S.J., Atkinson K. Mesenchymal stem cells: immunobiology and therapeutic potential in kidney disease. Nephrology (Carlton) 2007, 12:44-52.
14. Hou Y., Ryu C.H., Jun J.A., Kim S.M., Jeong C.H., Jeun S.-S. IL-8 enhances the angiogenic potential of human bone marrow mesenchymal stem cells by increasing vascular endothelial growth factor. Cell Biol Int 2014, 38:1050-1059.
15. Guiducci S., Manetti M., Romano E., Mazzanti B., Ceccarelli C., Dal Pozzo S., et al. Bone marrow-derived mesenchymal stem cells from early diffuse systemic sclerosis exhibit a paracrine machinery and stimulate angiogenesis invitro. Ann Rheum Dis 2011, 70:2011-2021.
16. Quevedo H.C., Hatzistergos K.E., Oskouei B.N., Feigenbaum G.S., Rodriguez J.E., Valdes D., et al. Allogeneic mesenchymal stem cells restore cardiac function in chronic ischemic cardiomyopathy via trilineage differentiating capacity. PNAS 2009, 106:14022-14027.
17. Barbash I.M., Chouraqui P., Baron J., Feinberg M.S., Etzion S., Tessone A., et al. Systemic delivery of bone marrow-derived mesenchymal stem cells to the infarcted myocardium: feasibility, cell migration, and body distribution. Circulation 2003, 108:863-868.
18. De Ugarte D.A., Alfonso Z., Zuk P.A., Elbarbary A., Zhu M., Ashjian P., et al. Differential expression of stem cell mobilization-associated molecules on multi-lineage cells from adipose tissue and bone marrow. Immunology Letters 2003, 89:267-270.
19. Ip J.E., Wu Y., Huang J., Zhang L., Pratt R.E., Dzau V.J. Mesenchymal Stem Cells Use Integrin β1 Not CXC Chemokine Receptor 4 for Myocardial Migration and Engraftment. Mol Biol Cell 2007, 18:2873-2882.
20. Rüster B., Göttig S., Ludwig R.J., Bistrian R., Müller S., Seifried E., et al. Mesenchymal stem cells display coordinated rolling and adhesion behavior on endothelial cells. Blood 2006, 108:3938-3944.
21. Wu Y., Zhao R.C.H. The role of chemokines in mesenchymal stem cell homing to myocardium. Stem Cell Rev 2012, 8:243-250.
22. Ghadge S.K., Mühlstedt S., Ozcelik C., Bader M. SDF-1α as a therapeutic stem cell homing factor in myocardial infarction. Pharmacol Ther 2011, 129:97-108.
23. Theiss H.D., Vallaster M., Rischpler C., Krieg L., Zaruba M.-M., Brunner S., et al. Dual stem cell therapy after myocardial infarction acts specifically by enhanced homing via the SDF-1/CXCR4 axis. Stem Cell Res 2011, 7:244-255.
24. Pal R., Hanwate M., Totey S.M. Effect of holding time, temperature and different parenteral solutions on viability and functionality of adult bone marrow-derived mesenchymal stem cells before transplantation. JTissue Eng Regen Med 2008, 2:436-444.
25. Ringe J., Kaps C., Schmitt B., Büscher K., Bartel J., Smolian H., et al. Porcine mesenchymal stem cells. Induction of distinct mesenchymal cell lineages. Cell Tissue Res 2002, 307:321-327.
26. Tropel P., Noël D., Platet N., Legrand P., Benabid A.-L., Berger F. Isolation and characterisation of mesenchymal stem cells from adult mouse bone marrow. Exp Cell Res 2004, 295:395-406.
27. Gregory C.A., Prockop D.J., Spees J.L. Non-hematopoietic bone marrow stem cells: molecular control of expansion and differentiation. Exp Cell Res 2005, 306:330-335.
28. International conference on harmonisation of technical requirements for registration of pharmaceuticals for human use: Validation of analytical procedures: text and methodology Q2(R1) Current Step 4 version Parent Guideline dated 27 October 1994. (Complementary Guideline on Methodology dated 6 November 1996 incorporated in November 2005).
29. Indian Pharmacopoeia 2010, Government of India, Ministry of Health and Family Welfare, Published by The Indian pharmacopoeia Commission Ghaziabad, 2010,6th Edition, Volume I, Section2,2. 2.11,page 56-63.
30. Lalu M.M., McIntyre L., Pugliese C., Fergusson D., Winston B.W., Marshall J.C., et al. Safety of cell therapy with mesenchymal stromal cells (SafeCell): a systematic review and meta-analysis of clinical trials. PLoS ONE 2012, 7:e47559.
31. Lee J.S., Hong J.M., Moon G.J., Lee P.H., Ahn Y.H., Bang O.Y., et al. Along-term follow-up study of intravenous autologous mesenchymal stem cell transplantation in patients with ischemic stroke. Stem Cells 2010, 28:1099-1106.
32. Bernardo M.E., Zaffaroni N., Novara F., Cometa A.M., Avanzini M.A., Moretta A., et al. Human bone marrow derived mesenchymal stem cells do not undergo transformation after long-term invitro culture and do not exhibit telomere maintenance mechanisms. Cancer Res 2007, 67:9142-9149.
33. Traverse J.H., Henry T.D., Moye' L.A. Is the measurement of left ventricular ejection fraction the proper end point for cell therapy trials? An analysis of the effect of bone marrow mononuclear stem cell administration on left ventricular ejection fraction after ST-segment elevation myocardial infarction when evaluated by cardiac magnetic resonance imaging. Am Heart J 2011, 162:671-677.
34. Mistry N., Halvorsen S., Hoffmann P., Müller C., Bøhmer E., Kjeldsen S.E., et al. Assessment of left ventricular function with magnetic resonance imaging vs. echocardiography, contrast echocardiography, and single-photon emission computed tomography in patients with recent ST-elevation myocardial infarction. Eur J Echocardiogr 2010, 11:793-800.
35. Bellenger N.G., Burgess M.I., Ray S.G., Lahiri A., Coats A.J., Cleland J.G., et al. Comparison of left ventricular ejection fraction and volumes in heart failure by echocardiography, radionuclide ventriculography and cardiovascular magnetic resonance; are they interchangeable?. Eur Heart J 2000, 21:1387-1396.
36. Martin P.J., Uberti J.P., Soiffer R.J., Klingemann H., Waller E.K., Daly A.S., et al. Prochymal Improves Response Rates In Patients With Steroid-Refractory Acute Graft Versus Host Disease (SR-GVHD) Involving The Liver And Gut: Results Of A Randomized, Placebo-Controlled, Multicenter Phase III Trial In GVHD. Biol Blood Marrow Transplant 2010, 16:S169-S170.
37. Weiss D.J., Casaburi R., Flannery R., LeRoux-Williams M., Tashkin D.P. Aplacebo-controlled, randomized trial of mesenchymal stem cells in COPD. Chest 2013, 143:1590-1598.
38. Traverse J.H., Henry T.D., Pepine C.J., Willerson J.T., Zhao D.X.M., Ellis S.G., et al. Effect of the use and timing of bone marrow mononuclear cell delivery on left ventricular function after acute myocardial infarction: the TIME randomized trial. JAMA 2012, 308:2380-2389.
39. Traverse J.H., Henry T.D., Ellis S.G., Pepine C.J., Willerson J.T., Zhao D.X.M., et al. Effect of intracoronary delivery of autologous bone marrow mononuclear cells 2 to 3 weeks following acute myocardial infarction on left ventricular function: the LateTIME randomized trial. JAMA 2011, 306:2110-2119.
40. Sürder D., Manka R., Lo Cicero V., Moccetti T., Rufibach K., Soncin S., et al. Intracoronary injection of bone marrow-derived mononuclear cells early or late after acute myocardial infarction: effects on global left ventricular function. Circulation 2013, 127:1968-1979.
41. Kinnaird T., Stabile E., Burnett M.S., Lee C.W., Barr S., Fuchs S., et al. Marrow-Derived Stromal Cells Express Genes Encoding a Broad Spectrum of Arteriogenic Cytokines and Promote InVitro and InVivo Arteriogenesis Through Paracrine Mechanisms. Cir Res 2004, 94:678-685.
42. Weimar I.S., Miranda N., Muller E.J., Hekman A., Kerst J.M., de Gast G.C., et al. Hepatocyte growth factor/scatter factor (HGF/SF) is produced by human bone marrow stromal cells and promotes proliferation, adhesion and survival of human hematopoietic progenitor cells (CD34+). Exp Hematol 1998, 26:885-894.
43. Cheng S.L., Zhang S.F., Mohan S., Lecanda F., Fausto A., Hunt A.H., et al. Regulation of insulin-like growth factors I and II and their binding proteins in human bone marrow stromal cells by dexamethasone. JCell Biochem 1998, 71:449-458.
44. Annex B.H. Therapeutic angiogenesis for critical limb ischaemia. Nat Rev Cardiol 2013, 10:387-396.
45. Hirsch A., Nijveldt R., van der Vleuten P.A., Tijssen J.G.P., van der Giessen W.J., Tio R.A., et al. Intracoronary infusion of mononuclear cells from bone marrow or peripheral blood compared with standard therapy in patients after acute myocardial infarction treated by primary percutaneous coronary intervention: results of the randomized controlled HEBE trial. Eur Heart J 2011, 32:1736-1747.
46. Schaefer A., Zwadlo C., Fuchs M., Meyer G.P., Lippolt P., Wollert K.C., et al. Long-term effects of intracoronary bone marrow cell transfer on diastolic function in patients after acute myocardial infarction: 5-year results from the randomized-controlled BOOST trial-an echocardiographic study. Eur J Echocardiogr 2010, 11:165-171.
47. Roncalli J., Mouquet F., Piot C., Trochu J.-N., Le Corvoisier P., Neuder Y., et al. Intracoronary autologous mononucleated bone marrow cell infusion for acute myocardial infarction: results of the randomized multicenter BONAMI trial. Eur Heart J 2011, 32:1748-1757.
48. Kuethe F., Figulla H.R., Herzau M., Voth M., Fritzenwanger M., Opfermann T., et al. Treatment with granulocyte colony-stimulating factor for mobilization of bone marrow cells in patients with acute myocardial infarction. Am Heart J 2005, 150:115.
49. Chen S., Fang W., Qian J., Ye F., Liu Y., Shan S. Improvement of cardiac function after transplantation of autologous bone marrow mesenchymal stem cells in patients with acute myocardial infarction. Chin Med J (Engl) 2004, 117:1443-1448.
50. Assmus B., Schächinger V., Teupe C., Britten M., Lehmann R., Döbert N., et al. Transplantation of Progenitor Cells and Regeneration Enhancement in Acute Myocardial Infarction (TOPCARE-AMI). Circulation 2002, 106:3009-3017.
51. Schächinger V., Assmus B., Erbs S., Elsässer A., Haberbosch W., Hambrecht R., et al. Intracoronary infusion of bone marrow-derived mononuclear cells abrogates adverse left ventricular remodelling post-acute myocardial infarction: insights from the reinfusion of enriched progenitor cells and infarct remodelling in acute myocardial infarction (REPAIR-AMI) trial. Eur J Heart Fail 2009, 11:973-979.
52. Huikuri H.V., Kervinen K., Niemelä M., Ylitalo K., Säily M., Koistinen P., et al. Effects of intracoronary injection of mononuclear bone marrow cells on left ventricular function, arrhythmia risk profile, and restenosis after thrombolytic therapy of acute myocardial infarction. Eur Heart J 2008, 29:2723-2732.
53. Clifford D.M., Fisher S.A., Brunskill S.J., Doree C., Mathur A., Watt S., et al. Stem cell treatment for acute myocardial infarction. Cochrane Database Syst Rev 2012, 2:CD006536.
54. Delewi R., Hirsch A., Tijssen J.G., Schächinger V., Wojakowski W., Roncalli J., et al. Impact of intracoronary bone marrow cell therapy on left ventricular function in the setting of ST-segment elevation myocardial infarction: a collaborative meta-analysis. Eur Heart J 2014, 35:989-998.
55. Hare J.M., Fishman J.E., Gerstenblith G., DiFede Velazquez D.L., Zambrano J.P., Suncion V.Y., et al. Comparison of allogeneic vs autologous bone marrow-derived mesenchymal stem cells delivered by transendocardial injection in patients with ischemic cardiomyopathy: the POSEIDON randomized trial. JAMA 2012, 308:2369-2379.